文献速递胃肠动力与功能性疾病

饮食疗法在非便秘型肠易激综合征中的疗效与可接受性:传统饮食建议、低FODMAP饮食与无麸质饮食的随机试验

Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-28

这项随机试验纳入罗马IV标准定义的非便秘型肠易激综合征患者,比较传统饮食建议(TDA)、低FODMAP饮食(LFD)与无麸质饮食(GFD)的疗效。主要终点为4周后IBS症状严重程度评分(IBS-SSS)降低≥50分,TDA组42%、LFD组55%、GFD组58%达到(P=.43)。结论认为三种饮食均有效,但TDA在费用和便利性上最受患者欢迎。

要点

  • TDA组42%达到IBS-SSS降低≥50分,LFD组55%,GFD组58%,组间无显著差异(P=.43)。
  • TDA较GFD和LFD更便宜(P<.01)、购物耗时更少(P<.01)、外出就餐更易遵循(P=.03)。
  • LFD组总FODMAP摄入量降幅最大(27.7降至7.6 g/天),高于GFD和TDA组(P<.01)。

核心结论

  • TDA、LFD和GFD对非便秘型IBS均有效,但TDA在费用和便利性上最受患者欢迎。
  • 作者推荐TDA作为非便秘型IBS的首选饮食疗法,LFD和GFD根据患者偏好和专科营养师指导选用。

研究设计与样本

  • 随机试验纳入罗马IV标准定义的非便秘型IBS患者,随机分配至TDA、LFD或GFD组(GFD允许微量麸质交叉污染)。
  • 主要终点为4周饮食干预后IBS-SSS降低≥50分。

主要发现

  • 达到IBS-SSS降低≥50分的比例:TDA组42%(14/33),LFD组55%(18/33),GFD组58%(19/33),P=.43。
  • TDA较GFD和LFD更便宜(P<.01)、购物耗时更少(P<.01)、外出就餐更易遵循(P=.03);TDA较LFD更易融入日常生活(P=.02)。
  • LFD组总FODMAP摄入量降幅最大(干预前27.7 g/天降至第4周7.6 g/天),GFD组27.4降至22.4 g/天,TDA组24.9降至15.2 g/天(P<.01)。
  • 粪便菌群失调指数变化组间相似:22%-29%改善,35%-39%无变化,35%-40%加重(P=.99)。
  • 基线临床特征和粪便菌群失调指数未能预测饮食治疗反应。

临床怎么用

  • 作者建议TDA作为非便秘型IBS的首选饮食疗法。
  • 作者建议LFD和GFD根据患者具体偏好和专科营养师指导选用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Various diets are proposed as first-line therapies for non-constipated irritable bowel syndrome (IBS) despite insufficient or low-quality evidence. We performed a randomized trial comparing traditional dietary advice (TDA) against the low FODMAP diet (LFD) and gluten-free diet (GFD). METHODS: Patients with Rome IV-defined non-constipated IBS were randomized to TDA, LFD, or GFD (the latter allowing for minute gluten cross-contamination). The primary end point was clinical response after 4 weeks of dietary intervention, as defined by ≥50-point reduction in IBS symptom severity score (IBS-SSS). Secondary end points included (1) changes in individual IBS-SSS items within clinical responders, (2) acceptability and food-related quality of life with dietary therapy, (3) changes in nutritional intake, (4) alterations in stool dysbiosis index, and (5) baseline factors associated with clinical response. RESULTS: The primary end point of ≥50-point reduction in IBS-SSS was met by 42% (n = 14/33) undertaking TDA, 55% (n = 18/33) for LFD, and 58% (n = 19/33) for GFD (P = .43). Responders had similar improvements in IBS-SSS items regardless of their allocated diet. Individuals found TDA cheaper (P < .01), less time-consuming to shop (P < .01), and easier to follow when eating out (P = .03) than the GFD and LFD. TDA was also easier to incorporate into daily life than the LFD (P = .02). Overall reductions in micronutrient and macronutrient intake did not significantly differ across the diets. However, the LFD group had the greatest reduction in total FODMAP content (27.7 g/day before intervention to 7.6 g/day at week 4) compared with the GFD (27.4 g/day to 22.4 g/day) and TDA (24.9 g/day to 15.2 g/day) (P < .01). Alterations in stool dysbiosis index were similar across the diets, with 22%-29% showing reduced dysbiosis, 35%-39% no change, and 35%-40% increased dysbiosis (P = .99). Baseline clinical characteristics and stool dysbiosis index did not predict response to dietary therapy. CONCLUSIONS: TDA, LFD, and GFD are effective approaches in non-constipated IBS, but TDA is the most patient-friendly in terms of cost and convenience. We recommend TDA as the first-choice dietary therapy in non-constipated IBS, with LFD and GFD reserved according to specific patient preferences and specialist dietetic input. CLINICALTRIALS: gov: NCT04072991.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rej A, Sanders DS, Shaw CC, et al. Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet. Clin Gastroenterol Hepatol. 2022. PMID: 35240330. doi:10.1016/j.cgh.2022.02.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。